74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Dynavax Technologies Corp
Closed
SectorHealthcare
10.88 0.93
Overview
Share price change
24h
Min
10.56
Max
11.09
Income | -11M 7.1M |
|---|---|
Sales | -8.6M 72M |
P/E Sector Avg | 52.2 57.333 |
EPS | 0.05 |
Profit margin | 9.787 |
Employees | 405 |
EBITDA | 2.2M 12M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +129.81% upside |
Next Earnings | 6 May 2025 |
|---|
Market Cap | -420M 1.3B |
|---|---|
Previous open | 9.95 |
Previous close | 10.88 |
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Dynavax Technologies Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Dynavax Technologies Corp Forecast
Price Target
By TipRanks
129.81% upside
12 Months Forecast
Average 24.75 USD 129.81%
High 33 USD
Low 10 USD
Based on 5 Wall Street analysts offering 12 month price targets forDynavax Technologies Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Dynavax Technologies Corp
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
